Curaleaf Raises Hostile Bid for Aurora to US$5.00/Share, Extends Deadline to Dec 4
CURLF sits 81% above its 52-week low of $5.4 on elevated volume (3.1× avg).
Summary
Curaleaf raised its hostile bid for Aurora Cannabis by 25% to US$5.00 per share, extended the deadline to December 4, and included pro forma financials showing the combined company's scale.
Key Events · M&A and Partnerships · CURLF
-
Bid Increased 25% to US$5.00/Share
The hostile offer for Aurora Cannabis has been raised from US$4.00 to US$5.00 per share, comprising US$1.00 cash (up 33%) plus 0.4013 Curaleaf shares, with the cap price raised 20% to US$6.00.
-
Deadline Extended to December 4
The tender offer expiry was extended from December 1 to December 4, 2026, giving Aurora shareholders additional time to consider the enhanced terms.
-
Pro Forma Financials Disclosed
The filing includes detailed pro forma statements showing the combined company would have US$1.5 billion in LTM revenue, nearly US$350 million in LTM Adjusted EBITDA, and at least US$40 million in expected annual cost synergies.
-
86% Premium to Unaffected Price
The enhanced offer represents an 86% premium to Aurora's 30-day VWAP of US$2.75 as of August 10, 2026, and a 217% premium on an ex-cash basis.
Analysis · CURLF · Life Sciences
The hostile takeover offer for Aurora Cannabis has been increased by 25%, from US$4.00 to US$5.00 per share, and the tender deadline extended by three days to December 4, 2026. The enhanced offer includes US$1.00 in cash (up 33% from US$0.75) plus 0.4013 Curaleaf shares per Aurora share, with a raised cap price of US$6.00. This escalation comes after Aurora's board recommended rejection and refused to engage in due diligence. The filing also includes detailed pro forma financials showing the combined company would have over US$1.5 billion in LTM revenue and nearly US$350 million in LTM Adjusted EBITDA. The increased bid signals Curaleaf's determination to complete the acquisition despite Aurora's resistance, and the pro forma disclosures give Aurora shareholders concrete financial data to evaluate the offer.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 43.8% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $9.76 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.